Fabry disease and the heart: an overview of the natural history and the effect of enzyme replacement therapy

Болезнь Фабри и сердце: обзор естественного течения заболевания и эффекта ферментозаместительной терапии
Perry Elliott, J.J Shah
2005-03-01

Fabry diseasealpha-galactosidase A deficiencycardiac manifestationsenzyme replacement therapyleft ventricular hypertrophy
UNLABELLED: Fabry disease is a genetic disorder caused by the deficiency of alpha-galactosidase A, resulting in the lysosomal accumulation of glycosphingolipids. Fabry disease may result in cardiac, cerebral and renal complications. Cardiac abnormalities in patients with Fabry disease were first described in the 1960s. In the 1990s a form of Fabry disease confined to the heart was reported; however, this variant is extremely rare and a more appropriate concept is of cardiac predominance of the disease in some patients. Up to 60% of males with classic Fabry disease have cardiac abnormalities, including left ventricular hypertrophy, valvular dysfunction and conduction abnormalities. Recent data suggest that left ventricular mass and systolic function in patients with Fabry disease improve after 12 months of enzyme replacement therapy (ERT); however, many of the patients studied are relatively young and have mild cardiac abnormalities, suggesting that more research into the efficacy of ERT in older patients is necessary. CONCLUSION: Cardiac manifestations are common in patients with Fabry disease and are not confined to a 'cardiac variant' of the disease.
1
Cardiac involvement is common in classic Fabry disease, affecting up to 60% of males and including left ventricular hypertrophy, valvular dysfunction, and conduction abnormalities.
2
Fabry disease results from alpha-galactosidase A deficiency, causing lysosomal glycosphingolipid accumulation and potentially cardiac, cerebral, and renal complications.
3
Left ventricular mass and systolic function may improve after 12 months of enzyme replacement therapy, although evidence largely involves younger patients with mild cardiac disease.
4
Rather than a distinct cardiac-only variant, some patients exhibit cardiac predominance of systemic Fabry disease; a truly heart-confined form is extremely rare.
5
The efficacy of enzyme replacement therapy in older patients or those with more advanced cardiac abnormalities remains insufficiently established.

cardiac manifestations of Fabry disease in patients with classic Fabry disease

the natural history of cardiac abnormalities and their response to enzyme replacement therapy, including changes in left ventricular mass and systolic function

Publication Details
Publication Date
2005-03-01
Journal
Publisher
ISSN
Access Type
Author Information
Authors
Perry Elliott
J.J Shah
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%